Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulse Biosciences Inc PLSE

Healthcare Medical Devices
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it... see more

Recent & Breaking News (NDAQ:PLSE)

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

Business Wire June 3, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Business Wire May 23, 2022

Pulse Biosciences, Inc. Announces Changes to its Rights Offering

Business Wire May 19, 2022

Pulse Biosciences Reports First Quarter 2022 Financial Results

Business Wire May 11, 2022

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Business Wire May 4, 2022

Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022

Business Wire April 28, 2022

Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference

Business Wire April 26, 2022

PULSE BIOSCIENCES (PLSE) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Pulse Biosciences, Inc. for Potential Securities Fraud Violations and Breaches of Fiduciary Duty

Business Wire April 25, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

PR Newswire April 18, 2022

PLSE Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Pulse Biosciences, Inc. Shareholders of Class Action and Last Few Hours to Actively Participate

Newsfile April 18, 2022

PLSE DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important April 18 Deadline in Securities Class Action - PLSE

Newsfile April 18, 2022

Deadline Today: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 18, 2022

PULSE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Pulse Biosciences, Inc. and Encourages Investors to Contact the Firm

Business Wire April 15, 2022

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc. (PLSE)

Business Wire April 15, 2022

Deadline Monday Notice: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 15, 2022

PLSE Final Deadline: ROSEN, A Leading Law Firm, Encourages Pulse Biosciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action - PLSE

Newsfile April 15, 2022

PLSE DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action - PLSE

PR Newswire April 14, 2022

Pulse Biosciences, Inc. Announces Rights Offering

Business Wire April 14, 2022

Deadline Monday Reminder: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 14, 2022

PLSE DEADLINE ALERT: ROSEN, A TOP RANKED FIRM, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action - PLSE

Newsfile April 13, 2022